Redmile Group’s Cytokinetics CYTK Stock Holding History

Redmile Group’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-82,098	Closed	-$3.3M	–	52
2025 Q1	$3.3M	Sell	82,098 -10,500	-11%	-$483K	0.31%	43
2024 Q4	$4.36M	Sell	92,598 -4,518	-5%	-$235K	0.3%	46
2024 Q3	$5.13M	Sell	97,116 -14,751	-13%	-$822K	0.3%	46
2024 Q2	$6.06M	Sell	111,867 -49,733	-31%	-$3M	0.37%	46
2024 Q1	$11.3M	Buy	+161,600	New	+$12.5M	0.42%	53

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Redmile Group's CYTK Position: Q2 2025 in Review

Redmile Group sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 82,098 shares — an estimated $3.3M sold.

Redmile Group first reported a position in CYTK in Q1 2024 and held it in 5 quarters. The position peaked at $11.3M in Q1 2024. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

Redmile Group reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
Redmile Group sold 82,098 Cytokinetics shares in Q2 2025, an estimated $3.3M.
Redmile Group first reported a position in Cytokinetics in Q1 2024 and held it in 5 quarters.
Redmile Group's Cytokinetics position peaked at $11.3M in Q1 2024.
311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on Redmile Group's 13F filing for Q2 2025, filed 14 Aug 2025.